Stage‐related increase in PIM2 expression in mycosis fungoides
APMIS · 2024
DOI: 10.1111/apm.13423 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, 2024. Verfasst von Mie Holm Nielsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark. Hauptthemen laut MEDLINE: Mycosis Fungoides, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Aage Bang Foundation, Novo Nordisk Foundation, Danish Cancer Society.
Abstract (Originalsprache)
The oncogene PIM2 is upregulated in several malignancies but has never been investigated in mycosis fungoides (MF), the most common type of cutaneous T‐cell lymphoma (CTCL). PIM2 is a well‐known oncogene and is regulated by cell signaling pathways like the JAK/STAT‐ and NF‐kB‐pathway, key regulators in the pathogenesis of CTCL. The aim of this study was to examine the role of PIM2 in MF. PIM2 gene expression was measured in 81 formalin‐fixed paraffin‐embedded skin biopsies from patients with MF and 46 control biopsies from healthy skin (HS) and benign inflammatory skin disease (BID). Validation of PIM2 protein expression was performed on selected biopsies with immunohistochemical staining. We found a significant difference in gene expression levels between both early stage MF and HS ( p < 0.0001), and BID ( p < 0.0001). In addition, the PIM2 gene expression was higher in advanced‐stage MF compared to early stage disease ( p = 0.0001). No significant difference in gene expression levels was found between patients with and without disease progression. In conclusion, we found PIM2 expression is significantly increased in MF compared to controls, and in advanced‐stage MF compared to early stage MF. These findings could potentially have diagnostic value in discriminating early stage MF from BID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark.
- Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.
- Department of Dermatology, University Hospital, Kiel, Schleswig-Holstein, Germany.
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Mie Holm Nielsen
Förderung
- Aage Bang Foundation
- Novo Nordisk Foundation
- Danish Cancer Society
- Region Sjællands Sundhedsvidenskabelige Forskningsfond
- Kongelig Hofbuntmager Aage Bangs Fond
- Novo Nordisk Fonden
- Kræftens Bekæmpelse
Zitieren
APA
Nielsen, M. H., Nielsen, P. R., Bzorek, M., Eriksen, J. O., Wehkamp, U., Lindahl, L. M., Woetmann, A., Ødum, N., Litman, T., & Gjerdrum, L. M. R. (2024). Stage‐related increase in PIM2 expression in mycosis fungoides. APMIS. https://doi.org/10.1111/apm.13423
Vancouver
Nielsen MH, Nielsen PR, Bzorek M, Eriksen JO, Wehkamp U, Lindahl LM, et al. Stage‐related increase in PIM2 expression in mycosis fungoides. APMIS. 2024. doi:10.1111/apm.13423
BibTeX
@article{Nielsen2024,
author = {Nielsen, Mie Holm and Nielsen, Pia Rude and Bzorek, Michael and Eriksen, Jens Ole and Wehkamp, Ulrike and Lindahl, Lise Maria and Woetmann, Anders and Ødum, Niels and Litman, Thomas and Gjerdrum, Lise Mette Rahbek},
title = {Stage‐related increase in PIM2 expression in mycosis fungoides},
journal = {APMIS},
year = {2024},
doi = {10.1111/apm.13423}
}
EUVIMED